NKJO
MCID: ATN007
MIFTS: 66

Autoinflammation, Lipodystrophy, and Dermatosis Syndrome (NKJO) malady

Categories: Genetic diseases, Rare diseases, Eye diseases, Bone diseases, Skin diseases, Blood diseases, Muscle diseases

Aliases & Classifications for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Aliases & Descriptions for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:

Name: Autoinflammation, Lipodystrophy, and Dermatosis Syndrome 54 24 25 66 13
Nakajo-Nishimura Syndrome 24 25 56 66
Nakajo Syndrome 25 66 69
Jmp Syndrome 24 56 66
Nkjo 24 25 66
Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome 24 66
Chronic Atypical Neutrophilic Dermatosis-Lipodystrophy-Elevated Temperature Syndrome 50 56
Secondary Hypertrophic Osteoperiostosis with Pernio 56 66
Candle Syndrome 50 56
Inflammation 42 69
Candle 24 66
Aldd 24 25
Nns 56 66
Joint Contractures-Muscular Atrophy-Microcytic Anemia-Panniculitis-Associated Lipodystrophy Syndrome 56
Joint Contractures, Muscular Atrophy, Microcytic Anemia, and Panniculitis-Induced Lipodystrophy 24
Joint Contractures Muscular Atrophy Microcytic Anemia and Panniculitis-Induced Lipodystrophy 66
Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature 50
Japanese Autoinflammatory Syndrome with Lipodystrophy 25
Autoinflammation-Lipodystrophy-Dermatosis Syndrome 56
Proteasome-Associated Autoinflammatory Syndrome 56
Amyotrophy-Fat Tissue Anomaly Syndrome 56
Nodular Erythema with Digital Changes 66
Proteasome Disability Syndrome 56
Amyotrophy Fat Tissue Anomaly 50
Nakajo Nishimura Syndrome 50
Aldd Syndrome 56
Praas 56
Jasl 25

Characteristics:

Orphanet epidemiological data:

56
nakajo-nishimura syndrome
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal; Age of death: young Adult;
jmp syndrome
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;
candle syndrome
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Infancy,Neonatal; Age of death: any age;
proteasome disability syndrome
Inheritance: Autosomal recessive; Age of onset: Childhood,Infancy,Neonatal;

HPO:

32
autoinflammation, lipodystrophy, and dermatosis syndrome:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 54 256040
ICD10 via Orphanet 34 L98.8
ICD10 33 H01.9

Summaries for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

OMIM : 54 This autosomal recessive systemic autoinflammatory disorder is characterized by early childhood onset of annular... (256040) more...

MalaCards based summary : Autoinflammation, Lipodystrophy, and Dermatosis Syndrome, also known as nakajo-nishimura syndrome, is related to choroiditis and rheumatoid arthritis, and has symptoms including arthralgia, joint stiffness and muscle weakness. An important gene associated with Autoinflammation, Lipodystrophy, and Dermatosis Syndrome is PSMB8 (Proteasome Subunit Beta 8), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Glycerol and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include neutrophil, skin and bone, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Genetics Home Reference : 25 Nakajo-Nishimura syndrome is an inherited condition that affects many parts of the body and has been described only in the Japanese population. Beginning in infancy or early childhood, affected individuals develop red, swollen lumps (nodular erythema) on the skin that occur most often in cold weather; recurrent fevers; and elongated fingers and toes with widened and rounded tips (clubbing).

NIH Rare Diseases : 50 chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature, also known as candle syndrome, is a rare autoinflammatory condition. signs and symptoms generally develop during the first year of life and may include recurrent fevers, purpura, swollen eyelids, joint pain, contractures, developmental delay and progressive lipodystrophy. candle syndrome is often caused by changes (mutations) in the psmb8 gene and is inherited in an autosomal recessive manner. in some cases, the underlying genetic cause is unknown. there is currently no cure for the condition. treatment is based on the signs and symptoms present in each person. last updated: 11/18/2015

UniProtKB/Swiss-Prot : 66 Nakajo syndrome: An autosomal recessive autoinflammatory disorder characterized by early childhood onset of recurrent fever, joint stiffness and severe contractures of the hands and feet, and erythematous skin lesions with subsequent development of lipodystrophy and laboratory evidence of immune dysregulation. Accompanying features may include muscle weakness and atrophy, hepatosplenomegaly, and microcytic anemia.

Related Diseases for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Diseases related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 449)
id Related Disease Score Top Affiliating Genes
1 choroiditis 31.9 CCL2 CRP CXCL8 IL10 IL1B IL6
2 rheumatoid arthritis 31.3 CCL2 CRP CXCL8 ICAM1 IFNG IL10
3 hepatitis 30.2 IFNG IL10 IL6 TNF
4 nakajo syndrome 12.1
5 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 12.0
6 chronic orbital inflammation 12.0
7 acute orbital inflammation 11.9
8 bone inflammation disease 11.9
9 chronic inflammation of lacrimal passage 11.9
10 acute inflammation of lacrimal passage 11.9
11 jmp syndrome 11.9
12 diffuse large b-cell lymphoma with chronic inflammation 11.8
13 pars planitis 11.5
14 mastitis 11.4
15 myocarditis 11.4
16 panuveitis 11.4
17 dermatitis 11.4
18 tolosa-hunt syndrome 11.4
19 sialadenitis 11.3
20 orchitis 11.3
21 tenosynovitis 11.2
22 post-thrombotic syndrome 11.2
23 blepharitis 11.1
24 crohn's disease 11.1
25 vogt-koyanagi-harada disease 11.0
26 chorioretinitis 11.0
27 ulcerative colitis 11.0
28 lymphadenitis 11.0
29 retinitis 11.0
30 asthma 11.0
31 systemic lupus erythematosus 11.0
32 acute disseminated encephalomyelitis 11.0
33 temporal arteritis 11.0
34 polymyositis 11.0
35 meningitis 11.0
36 mucositis 10.9
37 fatty liver disease 10.9
38 encephalitis 10.9
39 birdshot chorioretinopathy 10.9
40 peritonitis 10.9
41 melorheostosis 10.8
42 mpv17-related hepatocerebral mitochondrial dna depletion syndrome 10.8
43 mitochondrial dna depletion syndrome 6 10.8
44 intussusception 10.4 IL1B TNF
45 unilateral multicystic dysplastic kidney 10.4 CRP IL6 TNF
46 swine influenza 10.4 CRP IL6 TNF
47 thymic neuroendocrine carcinoma 10.4 CXCL8 IL6 TNF
48 oculomotor nerve paralysis 10.4 CXCL8 IL1B IL6
49 microglandular adenosis of breast 10.4 CCL11 CXCL8 IL10
50 hidradenitis suppurativa 10.4 CCL11 CXCL8 IL10

Graphical network of the top 20 diseases related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:



Diseases related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Symptoms & Phenotypes for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Symptoms by clinical synopsis from OMIM:

256040

Clinical features from OMIM:

256040

Human phenotypes related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:

56 32 (show top 50) (show all 55)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 arthralgia 56 32 Very frequent (99-80%) HP:0002829
2 joint stiffness 56 32 Very frequent (99-80%) HP:0001387
3 muscle weakness 56 32 Frequent (79-30%) HP:0001324
4 abnormal pyramidal signs 56 32 Occasional (29-5%) HP:0007256
5 hyperhidrosis 56 32 Frequent (79-30%) HP:0000975
6 respiratory insufficiency 56 32 Occasional (29-5%) HP:0002093
7 macroglossia 56 32 Occasional (29-5%) HP:0000158
8 macrotia 56 32 Occasional (29-5%) HP:0000400
9 splenomegaly 56 32 Very frequent (99-80%) HP:0001744
10 hepatomegaly 56 32 Very frequent (99-80%) HP:0002240
11 intellectual disability, mild 56 32 Occasional (29-5%) HP:0001256
12 subcutaneous nodule 56 32 Very frequent (99-80%) HP:0001482
13 cardiomegaly 56 32 Occasional (29-5%) HP:0001640
14 lipoatrophy 56 32 Very frequent (99-80%) HP:0100578
15 arrhythmia 56 32 Occasional (29-5%) HP:0011675
16 skeletal muscle atrophy 56 32 Frequent (79-30%) HP:0003202
17 thick lower lip vermilion 56 32 Occasional (29-5%) HP:0000179
18 congestive heart failure 56 32 Occasional (29-5%) HP:0001635
19 microcytic anemia 56 32 Occasional (29-5%) HP:0001935
20 arthrogryposis multiplex congenita 56 32 Very frequent (99-80%) HP:0002804
21 arachnodactyly 56 32 Occasional (29-5%) HP:0001166
22 skin rash 56 32 Very frequent (99-80%) HP:0000988
23 hyperostosis 56 32 Very frequent (99-80%) HP:0100774
24 clubbing of toes 56 32 Frequent (79-30%) HP:0100760
25 lymphadenopathy 56 32 Frequent (79-30%) HP:0002716
26 prominent nose 56 32 Occasional (29-5%) HP:0000448
27 abnormality of the leydig cells 56 32 Very frequent (99-80%) HP:0010789
28 increased antibody level in blood 56 32 Frequent (79-30%) HP:0010702
29 right bundle branch block 56 32 Occasional (29-5%) HP:0011712
30 elevated erythrocyte sedimentation rate 56 32 Very frequent (99-80%) HP:0003565
31 erythema nodosum 56 32 Very frequent (99-80%) HP:0012219
32 lipodystrophy 56 32 Very frequent (99-80%) HP:0009125
33 episodic fever 56 32 Very frequent (99-80%) HP:0001954
34 clubbing of fingers 56 32 Frequent (79-30%) HP:0100759
35 fever 56 Very frequent (99-80%)
36 seizures 32 HP:0001250
37 bone pain 32 HP:0002653
38 osteopenia 32 HP:0000938
39 failure to thrive 32 HP:0001508
40 short stature 32 HP:0004322
41 hypertriglyceridemia 32 HP:0002155
42 elevated hepatic transaminases 32 HP:0002910
43 abnormality of the face 56 Very frequent (99-80%)
44 erythema 32 HP:0010783
45 conjunctivitis 32 HP:0000509
46 camptodactyly of finger 32 HP:0100490
47 flexion contracture of toe 32 HP:0005830
48 episcleritis 32 HP:0100534
49 hyperpigmentation of the skin 32 HP:0000953
50 long fingers 32 HP:0100807

UMLS symptoms related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:


dyspepsia, meningism, polydipsia, muscle weakness, arthralgia, bone pain

GenomeRNAi Phenotypes related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 IL10 IL1B MPO PSMB8 TNF CXCL8
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 IL10 IL1B MPO PSMB8 TNF CXCL8

MGI Mouse Phenotypes related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:

44 (show all 15)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.41 ICAM1 IFNG IL10 IL13 IL1B IL4
2 immune system MP:0005387 10.41 CCL11 CCL2 CRP ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.37 CRP ICAM1 IFNG IL10 IL13 IL1B
4 cardiovascular system MP:0005385 10.33 SELE SETD2 TNF VCAM1 CRP ICAM1
5 growth/size/body region MP:0005378 10.3 SETD2 TNF VCAM1 ICAM1 IFNG IL10
6 mortality/aging MP:0010768 10.22 ICAM1 IFNG IL10 IL13 IL1B IL4
7 digestive/alimentary MP:0005381 10.19 ICAM1 IFNG IL10 IL13 IL4 IL5
8 integument MP:0010771 10.16 ICAM1 IFNG IL10 IL13 IL1B IL4
9 liver/biliary system MP:0005370 10.03 IFNG IL10 IL4 IL5 IL6 PTGS2
10 muscle MP:0005369 9.97 ICAM1 IFNG IL10 IL13 IL6 MPO
11 neoplasm MP:0002006 9.97 IL5 IL6 PSMB8 PTGS2 TNF ICAM1
12 reproductive system MP:0005389 9.91 IFNG IL10 IL13 IL4 IL5 IL6
13 respiratory system MP:0005388 9.85 CCL11 IFNG IL10 IL13 IL4 IL5
14 skeleton MP:0005390 9.61 IL1B IL4 IL6 PTGS2 SETD2 TNF
15 vision/eye MP:0005391 9.28 PTGS2 SELE SETD2 TNF ICAM1 IFNG

Drugs & Therapeutics for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Drugs for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1303)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glycerol Approved, Experimental Phase 4,Phase 2,Phase 3,Phase 1 56-81-5 753
2
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
3
Tobramycin Approved, Investigational Phase 4,Phase 3,Phase 1 32986-56-4 5496 36294
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 124-94-7 31307
5
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Early Phase 1 564-25-0 54671203
6
Colchicine Approved Phase 4,Phase 2,Phase 3,Phase 1 64-86-8 6167 2833
7
Ramipril Approved Phase 4,Phase 2,Phase 3 87333-19-5 5362129
8
Ticlopidine Approved Phase 4,Phase 2 55142-85-3 5472
9
Cetirizine Approved Phase 4,Phase 2 83881-51-0 2678
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 75614-87-8, 51-45-6 774
11
Montelukast Approved Phase 4,Phase 2,Phase 3,Phase 1 158966-92-8 5281040
12
Nitric Oxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 10102-43-9 145068
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-78-2 2244
14
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
15
Valsartan Approved, Investigational Phase 4,Phase 2 137862-53-4 60846
16
Everolimus Approved Phase 4,Phase 3,Phase 1,Phase 2 159351-69-6 6442177
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
18
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 53123-88-9 5284616 6436030 46835353
19
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
20
Lopinavir Approved Phase 4,Phase 1 192725-17-0 92727
21
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 1,Early Phase 1 155213-67-5 392622
22
Mannitol Approved, Investigational Phase 4,Phase 2,Phase 1 69-65-8 453 6251
23
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
24
Lisinopril Approved, Investigational Phase 4,Phase 3,Phase 2 83915-83-7 5362119
25
Desogestrel Approved Phase 4,Phase 2,Phase 3 54024-22-5 40973
26
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757 53477783
27
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
28
Etonogestrel Approved, Investigational Phase 4,Phase 2,Phase 3 54048-10-1 40976 6917715
29
Ipratropium Approved Phase 4 22254-24-6, 60205-81-4 43232
30
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 53-03-2 5865
31
Omalizumab Approved, Investigational Phase 4,Phase 2,Phase 3 242138-07-4
32
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2 144701-48-4 65999
33
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 111025-46-8 4829
34
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 83-43-2 6741
35
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-24-8 5755
36
Zinc Approved Phase 4,Phase 3,Phase 2,Phase 1 7440-66-6 32051 23994
37
Atenolol Approved Phase 4 29122-68-7 2249
38
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
39
Azithromycin Approved Phase 4,Phase 3,Phase 2,Phase 1 83905-01-5 55185 53477736 447043
40
Minocycline Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 10118-90-8 5281021
41
Abacavir Approved, Investigational Phase 4,Phase 3 136470-78-5 65140 441300
42
Maraviroc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 376348-65-1 3002977
43
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1 51-61-6, 62-31-7 681
44
Norepinephrine Approved Phase 4,Phase 2,Phase 1 51-41-2 439260
45
Apraclonidine Approved Phase 4 66711-21-5 2216
46
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 79902-63-9 54454
47
Acetylcysteine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 616-91-1 12035
48 Beractant Approved Phase 4 108778-82-1
49
Fluvastatin Approved Phase 4,Phase 3,Phase 2 93957-54-1 1548972
50
Bupivacaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2180-92-9, 38396-39-3 2474

Interventional clinical trials:

(show top 50) (show all 5012)
id Name Status NCT ID Phase
1 Fat, Inflammation and Insulin Resistance Unknown status NCT01054989 Phase 4
2 Efficacy Comparison Study of Steroids to Control Post-operative Inflammation Unknown status NCT01801774 Phase 4
3 Clinical Impact of Bacteriuria on Chronic Inflammation in Asymptomatic Hemodialysis Patients Unknown status NCT01570556 Phase 4
4 Doxycycline and Airway Inflammation in Chronic Obstructive Pulmonary Disease (COPD) Unknown status NCT00857038 Phase 4
5 Post-MI PET Scan Imaging of Inflammation Unknown status NCT02281305 Phase 4
6 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4
7 Comparison of the Effect of Montelukast and Cetirizine on Allergic Inflammation in Children With Allergic Rhinitis Unknown status NCT00488176 Phase 4
8 Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer Unknown status NCT01049295 Phase 4
9 Hormones Inflammation and Thrombosis Unknown status NCT01875185 Phase 4
10 Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Obstructive Chronic Pulmonary Disease (COPD) Phenotype Unknown status NCT01431625 Phase 4
11 Effects of DHA on Pro-resolving Anti-inflammatory Mediators in Obese Patients Undergoing Weight-loss Treatment Unknown status NCT01865448 Phase 4
12 Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery Unknown status NCT01046604 Phase 4
13 Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder Unknown status NCT01699490 Phase 4
14 Role of Healthy Bacteria in Ulcerative Colitis Unknown status NCT01479660 Phase 4
15 Effects of DES Platforms on Markers of Endothelial Damage and Inflammation Unknown status NCT01489202 Phase 4
16 Anti-inflammatory Effect of Atorvastatin in Atherosclerotic Plaques Assessed by FDG-PET Imaging Unknown status NCT00920101 Phase 4
17 Optimization of Inhaled Corticosteroid Treatment in Adult Patients With Asthma Guided by Exhaled NO Measurement at Home Unknown status NCT01783132 Phase 4
18 RAltegravir Switch STudy: Effects on Endothelial Recovery Unknown status NCT01453933 Phase 4
19 Effects of Hemofiltration and Mannitol Treatment on Cardiopulmonary-Bypass Induced Immunosuppression Unknown status NCT00426192 Phase 4
20 Effects of Montelukast in Asthmatic Children With and Without Food Allergy Unknown status NCT01618929 Phase 4
21 Mechanisms Underlying Postoperative Insulin Resistance and Inflammation Unknown status NCT01470534 Phase 4
22 Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI. Unknown status NCT00430040 Phase 4
23 Probiotic in Irritable Bowel Syndrome (IBS) Patients With Diarrhea Unknown status NCT01667627 Phase 4
24 Can Advair and Flovent Reduce Systemic Inflammation Related to Chronic Obstructive Pulmonary Disease (COPD)? A Multi-Center Randomized Controlled Trial Unknown status NCT00120978 Phase 4
25 Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers Unknown status NCT01448291 Phase 4
26 Type 2 Diabetes Mellitus and Atherosclerosis Unknown status NCT01250340 Phase 4
27 The HDL Particle Protection Study Unknown status NCT02125682 Phase 4
28 Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma Unknown status NCT00576069 Phase 4
29 Effects of the Ivabradine on Reduction of Inflammatory Markers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4
30 Egg Albumin-Based Protein Supplement Versus Renal-specific Supplement in Hemodialysis Patients Unknown status NCT01981083 Phase 4
31 Effect of Specific Immunotherapy to Dust Mites in Children With Asthma Unknown status NCT00496561 Phase 4
32 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
33 Effect of Xolair on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4
34 Telmisartan Versus Ramipril After Acute Coronary Syndrome Unknown status NCT00702936 Phase 4
35 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
36 Evaluation of Photodynamic Treatment FOTOSAN® Efficacy in Periodontology Unknown status NCT02030470 Phase 4
37 Pioglitazone Vs Placebo in Combination With Niacin Extended Release on Low HDL Unknown status NCT00300365 Phase 4
38 The Efficacy of Methylprednisolone in the Treatment of Patients With Ocular Involvement in Behcet's Disease Unknown status NCT01306955 Phase 4
39 Treatment of Coronary Atherosclerosis by Insulin Sensitizers in Insulin-Resistant Patients Unknown status NCT00155350 Phase 4
40 Perioperative Effect of Atenolol on Cytokine Profiles Unknown status NCT00202358 Phase 4
41 Does Rosuvastatin Delay Progression of Atherosclerosis in HIV Unknown status NCT01813357 Phase 4
42 Lipids of the Human Tear Film and Their Effect on Tear Stability Unknown status NCT00803452 Phase 4
43 Maraviroc Abacavir STudy - Effect on Endothelial Recovery Unknown status NCT01389063 Phase 4
44 Trial of Supplementation With Aged Garlic Extract to Improve Endothelial Function in Patients With Metabolic Syndrome Unknown status NCT01168700 Phase 4
45 Inflammatory Markers and Cognitive Function in Major Depression Unknown status NCT01391221 Phase 4
46 Exercise And Rosuvastatin Treatment: Is There an Anti-Inflammatory Synergy? Unknown status NCT00295373 Phase 4
47 Micropulse Laser Trabeculoplasty Versus Selective Laser Trabeculoplasty for Treatment of Open Angle Glaucoma Unknown status NCT01956942 Phase 4
48 FRC Guided Therapy in Acute Respiratory Failure Unknown status NCT01280019 Phase 4
49 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4
50 Simvastatin in Patients With Septic Shock Unknown status NCT00450840 Phase 4

Search NIH Clinical Center for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: inflammation

Genetic Tests for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

Genetic tests related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:

id Genetic test Affiliating Genes
1 Autoinflammation, Lipodystrophy, and Dermatosis Syndrome 24 PSMB8

Anatomical Context for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome

MalaCards organs/tissues related to Autoinflammation, Lipodystrophy, and Dermatosis Syndrome:

39
Neutrophil, Skin, Bone, Eye, Heart, Skeletal Muscle

Publications for Autoinflammation, Lipodystrophy, and Dermatosis Syndrome